Synapse - The association between tumor mutational burden and prognosis is dependent on treatment context

The association between tumor mutational burden and prognosis is dependent on treatment context Research Letter

Authors:	Valero, C.; Lee, M.; Hoen, D.; Wang, J.; Nadeem, Z.; Patel, N.; Postow, M. A.; Shoushtari, A. N.; Plitas, G.; Balachandran, V. P.; Smith, J. J.; Crago, A. M.; Long Roche, K. C.; Kelly, D. W.; Samstein, R. M.; Rana, S.; Ganly, I.; Wong, R. J.; Hakimi, A. A.; Berger, M. F.; Zehir, A.; Solit, D. B.; Ladanyi, M.; Riaz, N.; Chan, T. A.; Seshan, V. E.; Morris, L. G. T.
Title:	The association between tumor mutational burden and prognosis is dependent on treatment context
Abstract:	In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 20% ICI-treated) with 17 cancer types before/without ICI treatment or after ICI treatment. In non-ICI-treated patients, higher TMB (higher percentile within cancer type) was not associated with better prognosis; in fact, in many cancer types, higher TMB was associated with poorer survival, in contrast to ICI-treated patients in whom higher TMB was associated with longer survival. © 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
Journal Title:	Nature Genetics
Volume:	53
Issue:	1
ISSN:	1061-4036
Publisher:	Nature Publishing Group
Date Published:	2021-01-01
Start Page:	11
End Page:	15
Language:	English
DOI:	10.1038/s41588-020-00752-4
PROVIDER:	scopus
PMCID:	PMC7796993
PUBMED:	33398197
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098624908&doi=10.1038%2fs41588-020-00752-4&partnerID=40&md5=0f5b7673be9aac38e267852a164dd770
Notes:	Article -- Export Date: 1 February 2021 -- Source: Scopus